Fig. 9

TFEB acetylation at K310 is reduced in AD patients and PS19 mice and inhibiting HDAC7 can restore TFEB acetylation in PS19 mice. A, B Western blotting analysis and quantification of ac-K310 and total TFEB in the brain lysates of AD patients and control individuals. n = 7 per group. C, D Western blotting analysis and quantification of ac-K310 and total TFEB in the hippocampus of 7- and 9-month-old WT and PS19 mice treated with TMP195 or vehicle. n = 3 (WT-Veh), 3 (WT-TMP195), 4 (PS19-Veh), 4 (PS19-TMP195). E Representative immunostaining images of ac-K310 in the hippocampus of WT and PS19 mice injected with AAV-G1-shHDAC7-GFP (shHD7) or AAV-G1-GFP. Scale bar = 20 μm. F Quantification of ac-K310 intensity in GFP⁺ cells. n = 39 (WT-Vec), 42 (WT-shHD7), 42 (PS19-Vec), 43 (PS19-shHD7). Statistical significance was determined by unpaired Student’s t test (B) or one-way ANOVA with Tukey’s post hoc analysis (D and F). Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n. s, not significant